Core Viewpoint - Nanjing Pharmaceutical (688189) is expanding its marketing network and product offerings in response to market demands, particularly in the flu treatment sector, while also initiating a share buyback program to enhance shareholder value [1][2][3] Group 1: Company Performance - As of May 30, 2025, Nanjing Pharmaceutical's stock closed at 7.06 yuan, with a 1.0% increase, a turnover rate of 3.09%, a trading volume of 84,700 shares, and a transaction value of 60.0036 million yuan [1] - On the same day, the net inflow of main funds was 6.1534 million yuan, while retail investors experienced a net outflow of 6.5781 million yuan [3] Group 2: Share Buyback Announcement - The company announced its first share buyback on May 30, 2025, repurchasing 142,114 shares, which is 0.05% of the total share capital of 274.4 million shares, at a total cost of approximately 1,003,764.13 yuan [2][3] - The buyback was approved during the board meeting on April 28, 2025, with a planned budget of between 10 million and 20 million yuan, and a maximum buyback price set at 9.53 yuan per share, to be completed within 12 months [2]